SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon

Abstract

Type I Interferons (IFN-Is) are a family of cytokines which play a major role in inhibiting viral infection. Resultantly, many viruses have evolved mechanisms in which to evade the IFN-I response. Here we tested the impact of expression of 27 different SARS-CoV-2 genes in relation to their effect on IFN production and activity using three independent experimental methods. We identified six gene products; NSP6, ORF6, ORF7b, NSP1, NSP5 and NSP15, which strongly (>10-fold) blocked MAVS-induced (but not TRIF-induced) IFNβ production. Expression of the first three of these SARS-CoV-2 genes specifically blocked MAVS-induced IFNβ-promoter activity, whereas all six genes induced a collapse in IFNβ mRNA levels, corresponding with suppressed IFNβ protein secretion. Five of these six genes furthermore suppressed MAVS-induced activation of IFNλs, however with no effect on IFNα or IFNγ production. In sharp contrast, SARS-CoV-2 infected cells remained extremely sensitive to anti-viral activity exerted by added IFN-Is. None of the SARS-CoV-2 genes were able to block IFN-I signaling, as demonstrated by robust activation of Interferon Stimulated Genes (ISGs) by added interferon. This, despite the reduced levels of STAT1 and phospho-STAT1, was likely caused by broad translation inhibition mediated by NSP1. Finally, we found that a truncated ORF7b variant that has arisen from a mutant SARS-CoV-2 strain harboring a 382-nucleotide deletion associating with mild disease (Δ382 strain identified in Singapore & Taiwan in 2020) lost its ability to suppress type I and type III IFN production. In summary, our findings support a multi-gene process in which SARS-CoV-2 blocks IFN-production, with ORF7b as a major player, presumably facilitating evasion of host detection during early infection. However, SARS-CoV-2 fails to suppress IFN-I signaling thus providing an opportunity to exploit IFN-Is as potential therapeutic antiviral drugs.

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review

“…SARS-CoV nsp-1 (nanostructural protein 1) suppresses the immune response along with the generation of IFNs (IFN-I). nsp demonstrates an elevated expression of IFN-I [ 83 ]. Activation of IFN-I also minimize the expression of viral proteins such as nsp1, nsp7, and nsp15, as well as ORFs such as ORF3B, ORF6, and ORF9b [ 84 ].…”

Structural biology of SARS-CoV-2: open the door for novel therapies

“… 196 Moreover, Nsp6 can strongly blocked MAVS (mitochondrial antiviral signaling protein)-induced interferon β production and binds TANK binding kinase1 (TBK1) to suppress interferon regulatory factor 3 (IRF3). 197 , 198 Nsp6 also interacts with the sigma-1 receptor, which is considered an effective candidate host protein for host-based repurposing approaches to treat COVID-19 patients. 199 So far, there is no available structural information for Nsp6.…”

Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19

“…Among these, nucleocapside (N) protein impedes type I IFN signaling by preventing the nuclear translocation of phosphorylated STAT1 and STAT2 [21] . A recent study identified six SARS-CoV-2 genes that block mitochondrial antiviral signaling protein (MAVS)-induced production of IFN-β, but not of IFN-α or IFN-γ [22] . Studies comparing peripheral immune responses in mild and severe COVID-19 patients report diminished type I IFN levels in severe cases versus mild cases, and restricted IFN-stimulated gene (ISG) expression among circulating immune cells [23] , [24] , [25] .…”